All eyes on healthcare as UK reacts to tax regime
This article was originally published in Clinica
The UK government is facing calls to bring forward a review of the business tax regime, due to take place later this year, amid concern that it might be pushing away some of the most important UK-based companies. The warnings from industry observers, including the influential Confederation of British Industries (CBI), came as pharmaceutical giant Shire and other major firms announced plans to relocate to Ireland.
You may also be interested in...
Australian patients with phototoxicity due to the rare condition EPP will now have their first treatment option – provided the drug's developer, Clinuvel, secures reimbursement under the Pharmaceutical Benefits Scheme.
Roche has partnered with Regeneron and Atea, but the company continues to leverage its long legacy in infectious diseases to identify good treatment options for the novel coronavirus.
Resilience has raised $800m to develop new technologies to manufacture complex drugs including vaccines, cell therapies and gene therapies.